New hope for Hard-to-Treat prostate cancer? early trial underway
NCT ID NCT04428788
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new drug called CC-94676 in 131 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to standard hormone therapy. The main goal was to check safety and find the right dose, while also looking for signs that the drug might shrink tumors or lower PSA levels. Results will help decide if further studies are warranted.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CC-94676 (also known as BMS-986365)
What this could lead to
If this drug proves safe and effective, it could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early phase 1 trial focused on safety and dosing, so it is too soon to know if CC-94676 will work. Side effects are unknown, and many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 101
San Antonio, Texas, 78229, United States
-
Local Institution - 102
Grand Rapids, Michigan, 49546, United States
-
Local Institution - 103
Sarasota, Florida, 34232, United States
-
Local Institution - 104
Boston, Massachusetts, 02215, United States
-
Local Institution - 105
New York, New York, 10065, United States
-
Local Institution - 106
Durham, North Carolina, 27710, United States
-
Local Institution - 107
Dallas, Texas, 75235, United States
-
Local Institution - 108
Baltimore, Maryland, 21287, United States
-
Local Institution - 109
New York, New York, 10032, United States
-
Local Institution - 111
Madison, Wisconsin, 53792, United States
-
Local Institution - 112
New York, New York, 10029, United States
-
Local Institution - 113
Philadelphia, Pennsylvania, 19104, United States
-
Local Institution - 115
Seattle, Washington, 98109, United States
-
Local Institution - 116
Stanford, California, 94305-5826, United States
-
Local Institution - 117
Ann Arbor, Michigan, 48109, United States
-
Local Institution - 119
Houston, Texas, 77030, United States
-
Local Institution - 120
Allentown, Pennsylvania, 18103, United States
-
Local Institution - 121
Thomasville, Georgia, 31792, United States
-
Local Institution - 122
Washington D.C., District of Columbia, 20010, United States